4.7 Article

Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer

期刊

BIOMEDICINES
卷 10, 期 4, 页码 -

出版社

MDPI
DOI: 10.3390/biomedicines10040732

关键词

ganglioside; cancer; resistance; squamous cell carcinoma

资金

  1. ISCIII Projects [PI19/00349, DTS19/00033]
  2. ERDF/ESF, Investing in your future
  3. COST action [Nano2Clinic CA17140, INNVAL 19/12, INNVAL20/13]
  4. NanoBioApp Research Network [MINECO-17-MAT201681955-REDT]

向作者/读者索取更多资源

Head and neck squamous cell carcinoma is a difficult-to-treat cancer with high recurrence rates. The expression of GB3 appears in neoplastic cells from the early stages of transformation, making it a reliable marker for early identification and targeted therapies for this type of cancer.
Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据